FTC Redefines Which Drug Patent Deals Need Antitrust OK
The Federal Trade Commission has revised the rules dictating when pharmaceutical companies must report a transfer of exclusive patent rights to the U.S. Department of Justice and the FTC for antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article